Cumulus cloud

Celerant® Earns Fall 2023 Top Performer Award from SourceForge

Retrieved on: 
Thursday, November 30, 2023
Sale, Assistant, Point, SourceForge, Cumulus cloud, Marketing, E-commerce, Software, Online shopping, Cryptocurrency, Celerity IT

ISELIN, N.J., Nov. 30, 2023 /PRNewswire-PRWeb/ -- Celerant Technology, a leader in retail technology and eCommerce solutions, is proud to announce it has been awarded a Fall 2023 Top Performer Award by SourceForge, the world's largest software and services review and comparison website. This award honors outstanding companies and products that rank in the top tenth percentile of highly-rated products on SourceForge.

Key Points: 
  • ISELIN, N.J., Nov. 30, 2023 /PRNewswire-PRWeb/ -- Celerant Technology, a leader in retail technology and eCommerce solutions, is proud to announce it has been awarded a Fall 2023 Top Performer Award by SourceForge, the world's largest software and services review and comparison website.
  • This award honors outstanding companies and products that rank in the top tenth percentile of highly-rated products on SourceForge.
  • I'm excited to award the Fall 2023 Top Performers on SourceForge.
  • -Logan Abbott, President of SourceForge
    "I'm excited to award the Fall 2023 Top Performers on SourceForge," stated Logan Abbott, President of SourceForge.

THE CUMULUS COFFEE COMPANY BRINGS PREMIUM COLD BREW TO THE HOME

Retrieved on: 
Thursday, November 16, 2023
Maveron, Research, Cumulus cloud, Mesh, Science, Ice, Coffee, Starbucks

NEW YORK, Nov. 16, 2023 /PRNewswire/ -- The Cumulus Coffee Company announced today that it will soon be introducing the first-ever solution for making premium cold brew at home in a matter of seconds. The company also announced it has raised $20.3M in seed funding led by Valor Siren Ventures and Valor Equity Partners, with participation from investors including Maveron, Howard Schultz, Linden Ventures, Carter Reum, and Ryan Tedder. This pivotal moment in the evolution of cold coffee is the result of cutting-edge technology coupled with world-class expertise in the science and craft of coffee.

Key Points: 
  • The First-of-its-Kind Cold Coffee Company, Led by Experts in Coffee, Technology, and Design, Secures $20.3M in Seed Funding From Investors, Including Valor Equity Partners, Maveron, and Howard Schultz
    NEW YORK, Nov. 16, 2023 /PRNewswire/ -- The Cumulus Coffee Company announced today that it will soon be introducing the first-ever solution for making premium cold brew at home in a matter of seconds.
  • This pivotal moment in the evolution of cold coffee is the result of cutting-edge technology coupled with world-class expertise in the science and craft of coffee.
  • "Cumulus' opportunity to bring premium cold coffee beverages to the home is simply enormous and will raise the bar for cold brew coffee everywhere."
  • "The nitro cold brew coffee market is one of the fastest growing segments in the coffee space.

Cumulus Unveils New AI Tool To Instantly Digitize Work Procedures and Upskill Workers at London Build Expo

Retrieved on: 
Tuesday, November 14, 2023
Language, Google Play, Cumulus cloud, History, AI, App Store (iOS/iPadOS), App store, Digital Systems, Medical device, Online shopping

Amid a severe skilled labor shortage, Cumulus AI enhances field productivity and upskills workers in three simple steps:

Key Points: 
  • Amid a severe skilled labor shortage, Cumulus AI enhances field productivity and upskills workers in three simple steps:
    Create.
  • Upload documents with existing work procedures and Cumulus AI will automatically transform them into digital workflows.
  • "Our customers have never seen anything like Cumulus AI before, and they are already lining up to start using it to digitize their work procedures and automate quality assurance."
  • To start your 30 day free trial, visit our pricing page or download Cumulus AI from the App Store or Google Play.

Cumulus CEO Matthew Kleiman Releases New Book Entitled "Work Done Right"

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, Systems analysis, Cumulus cloud, Work, Digital transformation, Management, Book, Amazon

WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- We are pleased to announce the release of Cumulus CEO Matthew Kleiman's new book, "Work Done Right: Using Systems Thinking To Guide Your Digital Transformation."

Key Points: 
  • WALTHAM, Mass., Oct. 31, 2023 /PRNewswire/ -- We are pleased to announce the release of Cumulus CEO Matthew Kleiman's new book, "Work Done Right: Using Systems Thinking To Guide Your Digital Transformation."
  • Published by Leaders Press, this highly anticipated book provides an innovative roadmap for using systems thinking to improve work quality and efficiency, specifically for industrial construction, manufacturing, and maintenance fields.
  • In "Work Done Right," systems analysis expert Matthew Kleiman draws on his extensive experience deploying powerful systems and technologies at scale in the aerospace and energy industries to provide a practical path forward.
  • The book was written specifically for:
    Order your copy today from Amazon.

Leveraging Digital Biomarkers to Generate Real-World Physiological and Behavioral Data in CNS Clinical Studies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 30, 2023
Alzheimer's disease, Central nervous system disease, Biomarker, Neuro, Disease, Doctor of Philosophy, CNS, Health, HIV disease progression rates, Artificial intelligence, Caregiver, Database, Schizophrenia, Machine learning, Neurology, ML, EEG, Neuropsychiatry, Patient, Bias, Diagnosis, Central nervous system, Medical imaging, Nursing, Cumulus cloud

TORONTO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into an (artificial intelligence) AI-based, multi-domain digital biomarker platform that is currently being leveraged in neurology and neuropsychiatry clinical trials. To date, the lack of objective measures in central nervous system (CNS) clinical studies has resulted in less than 6% of drugs in this space making it to market. Many of the validated cognitive assessments today are paper-based, introducing the potential for bias and limiting ethnic and geographic diversity in clinical studies. An additional challenge facing CNS studies is the higher-than-average patient drop-out rates, in large part due to the burden associated with attending clinical site visits.

Key Points: 
  • The featured speakers will discuss the power of longitudinal EEG data synchronized with behavioral assessment data and how this can accelerate clinical studies, saving time and budget.
  • TORONTO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into an (artificial intelligence) AI-based, multi-domain digital biomarker platform that is currently being leveraged in neurology and neuropsychiatry clinical trials.
  • Many of the validated cognitive assessments today are paper-based, introducing the potential for bias and limiting ethnic and geographic diversity in clinical studies.
  • An additional challenge facing CNS studies is the higher-than-average patient drop-out rates, in large part due to the burden associated with attending clinical site visits.

Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023
AD, Life, Behavior, Pathology, Amnesia, Doctor of Philosophy, CNS, Deficit spending, Health, Clinical trial, Personality, Poster, Dementia, Memory, Confusion, University, Language, Patient, Communication, Cognition, Medical device, Medical imaging, Alzheimer's disease, Disease, Cumulus cloud

Data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting provides further validation of the utility of Cumulus Neuroassessment Platform in clinical studies that include patients with mild to moderate cognitive impairment.

Key Points: 
  • Data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting provides further validation of the utility of Cumulus Neuroassessment Platform in clinical studies that include patients with mild to moderate cognitive impairment.
  • BELFAST, Ireland and CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data at the Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting on Wednesday October 25th in Boston, Massachusetts.
  • Cumulus presented three poster presentations, two featuring internally generated data collected from Cumulus-sponsored studies partnering with academic and clinical institutions, and one featuring data generated from a study sponsored by INmune Bio Inc. (Nasdaq: INMB) a clinical stage biopharma company.
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.

INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Retrieved on: 
Tuesday, October 17, 2023
Cross, Drug development, Biology, Brain, Trial of the century, CNS Drugs (journal), Remyelination, Proteome, Neurology, MOA, Clinical trial, Pharmacotherapy, Disease, EEG, CSF, Diffusion, Tau, Grey, MRI, Neuroinflammation, Patient, Cumulus cloud, Medical imaging, Pharmaceutical industry

Boca Raton, Florida, Oct. 17, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, highlights some important findings from data presented at the 16th annual Clinical Trial in Alzheimer’s Disease (CTAD) to be held October 24-27 in Boston, MA.

Key Points: 
  • INmune is enrolling AD patients into a global, blinded, randomized Phase II trial.
  • “The Phase Ib trial was designed to demonstrate that XPro™ reverses neuroinflammation and has been confirmed by previously presented data ,” said CJ Barnum Ph.D., VP of CNS Drug Development at INmune Bio.
  • P055: Changes in cortical microstructure in brain regions associated with cognitive status and disease duration after short-term treatment with XPro1595 for Alzheimer’s disease.
  • A goal of our Phase II study in Early AD patients is to correlate these biologic changes with cognitive function.”

Cumulus Neuroscience Presents Data at ECNP 2023 Annual Meeting

Retrieved on: 
Tuesday, October 10, 2023
TMS, Doctor of Philosophy, Neuropsychiatry, European College of Neuropsychopharmacology, Memory, Health, EEG, FDA, Data collection, MRI, Learning, LTP, CNS, ECNP, Patient, Medical imaging, Cumulus cloud

At-home pilot study confirmed real-world feasibility of low burden, remote measurement of neuroplasticity

Key Points: 
  • At-home pilot study confirmed real-world feasibility of low burden, remote measurement of neuroplasticity
    BELFAST, Ireland and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data from a feasibility pilot study at the European College of Neuropsychopharmacology (ECNP) Annual Meeting in Barcelona, Spain on October 10th.
  • Using the proprietary Cumulus Neuroassessment Platform to gather data via repeated at-home sampling, the study was conducted on behalf of a biopharma study sponsor.
  • LTP is a synaptic plasticity phenomenon related to learning and memory which is used widely in animal studies.
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.

Cumulus Neuroscience Presents Data at ECNP 2023 Annual Meeting

Retrieved on: 
Tuesday, October 10, 2023
TMS, Doctor of Philosophy, Neuropsychiatry, European College of Neuropsychopharmacology, Memory, Health, EEG, FDA, Data collection, MRI, Learning, LTP, CNS, ECNP, Patient, Medical imaging, Cumulus cloud

At-home pilot study confirmed real-world feasibility of low burden, remote measurement of neuroplasticity

Key Points: 
  • At-home pilot study confirmed real-world feasibility of low burden, remote measurement of neuroplasticity
    BELFAST, Ireland and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data from a feasibility pilot study at the European College of Neuropsychopharmacology (ECNP) Annual Meeting in Barcelona, Spain on October 10th.
  • Using the proprietary Cumulus Neuroassessment Platform to gather data via repeated at-home sampling, the study was conducted on behalf of a biopharma study sponsor.
  • LTP is a synaptic plasticity phenomenon related to learning and memory which is used widely in animal studies.
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.

Skytree Launches First Direct Air Capture Unit for Onsite CO2 Generation

Retrieved on: 
Thursday, September 14, 2023
Vaccine, Pioneer program, Food, Headache, Tokyo Skytree, CEA, Farmer, Eye, Direct air capture, Flower, Carbon, DAC, Climate change, Controlled-environment agriculture, CO2, Farm, Agriculture, Renewable energy, Propane, Cumulus cloud

AMSTERDAM, Sept. 14, 2023 /PRNewswire-PRWeb/ -- Skytree, a pioneering climate tech company dedicated to combating climate change through innovative CO2 capture and reutilization solutions, today announced the launch of Skytree Cumulus, the company's inaugural Direct Air Capture (DAC) modular unit. Once installed onsite at a vertical farm, greenhouse, or any Controlled Environment Agriculture (CEA) business, Skytree Cumulus captures CO2 from the ambient air and makes it available for use by indoor farmers and greenhouse growers in the production of food, algae, vaccines, and flowers.

Key Points: 
  • Skytree Cumulus is now available for ordering with the first units to ship in early 2024.
  • "This is an incredibly exciting moment for Skytree as we move forward with the commercialization of our first unit for onsite carbon capture and reutilization," said Rob van Straten, Skytree CEO.
  • "By enabling the generation of CO2 onsite at farms and greenhouses, we are taking a significant step forward in helping CEA businesses reduce their carbon footprint and transition away from the fossil fuel industry as a source for CO2 supply."
  • Capable of generating up to 400 kg of CO2 per day, Skytree expects the larger unit to become available in the second half of 2024.